Comparative Pharmacology
Head-to-head clinical analysis: ADLYXIN versus WEGOVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLYXIN versus WEGOVY.
ADLYXIN vs WEGOVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Semaglutide, a GLP-1 receptor agonist, increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and reduces appetite via central GLP-1 receptor activation.
Subcutaneous injection: 10 mcg once daily within 60 minutes before the first meal of the day; may increase to 20 mcg once daily after 2 weeks.
Subcutaneous injection 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly for 4 weeks, then 1 mg once weekly for 4 weeks, then 1.7 mg once weekly for 4 weeks, then maintenance 2.4 mg once weekly.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours after subcutaneous administration, supporting a twice-daily dosing regimen.
Terminal elimination half-life is approximately 1 week (6–8 days), supporting once-weekly subcutaneous dosing.
Renal (predominantly via glomerular filtration and proteolytic degradation; approximately 35% of the dose is excreted unchanged in urine, with the remainder as metabolites and small peptides).
Primarily renal; approximately 97% of the dose is excreted unchanged in urine, with less than 3% in feces via biliary excretion.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist